Informet LA Tablet 750 mg contains Metformin Hydrochloride in a long-acting (LA) or extended-release formulation. It is an oral antidiabetic medicine primarily used in the management of type 2 diabetes mellitus. The long-acting design allows the medicine to be released gradually over time, helping to maintain stable blood glucose control throughout the day while improving gastrointestinal tolerability compared to immediate-release metformin.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Biguanides
Oral Antidiabetic Agent

Composition

Each tablet contains Metformin Hydrochloride 750 mg (extended-release).

Indications

Informet LA Tablet 750 mg is indicated for:

• Management of type 2 diabetes mellitus in adults

• Use as monotherapy or in combination with other oral antidiabetic agents or insulin

• Improving glycemic control when diet and exercise alone are insufficient

It is particularly suitable for patients who require once-daily dosing and better gastrointestinal tolerance.

Pharmacology

Metformin is a biguanide antidiabetic agent that lowers blood glucose levels without causing significant hypoglycemia. It works through multiple mechanisms:

• Decreases hepatic glucose production (gluconeogenesis)

• Reduces intestinal absorption of glucose

• Improves insulin sensitivity by increasing peripheral glucose uptake and utilization

The extended-release formulation of Informet LA ensures slow and steady release of metformin, resulting in prolonged therapeutic effect and reduced peak plasma concentration, which helps minimize common side effects such as nausea and diarrhea.

Dosage and Administration

The dosage of Informet LA Tablet 750 mg should be individualized based on the patient’s blood glucose levels and clinical response.

• Usually taken once daily with the evening meal

• Tablets should be swallowed whole and not crushed or chewed

Dose adjustments should be made gradually to reduce gastrointestinal side effects. Always follow the advice of a registered healthcare professional.

Contraindications

Informet LA Tablet 750 mg is contraindicated in patients with:

• Severe renal impairment

• Acute or chronic metabolic acidosis, including diabetic ketoacidosis

• Known hypersensitivity to metformin

Precautions and Warnings

• Renal function should be assessed before starting therapy and monitored regularly

• Use with caution in elderly patients

• Temporary discontinuation may be required before major surgery or radiological procedures involving iodinated contrast media

• Risk of lactic acidosis, though rare, should be considered, especially in patients with renal or hepatic impairment

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Adverse Effects

Common side effects may include:

• Nausea

• Diarrhea

• Abdominal discomfort

• Loss of appetite

These effects are usually mild and transient, particularly with the extended-release formulation. Long-term use may be associated with vitamin B12 deficiency.

Drug Interactions

Caution is advised when used with:

• Alcohol

• Iodinated contrast agents

• Certain antihypertensive or diuretic medicines

Concomitant use with other antidiabetic agents may increase the risk of hypoglycemia.

Storage

Store in a cool and dry place, protected from light and moisture. Keep out of reach of children.

Conclusion

Informet LA Tablet 750 mg is an effective and well-tolerated extended-release formulation of metformin, designed to provide sustained blood glucose control with convenient once-daily dosing. It plays a key role in the long-term management of type 2 diabetes mellitus, especially in patients who benefit from improved gastrointestinal tolerability and consistent glycemic control.